Introduction of human papillomavirus vaccination in Belgium, Luxembourg and The Netherlands

Gynecologic and Obstetric Investigation

Volumn 70, Issue 4, 2010, Pages 224-232

  Arbyn, M ^a   Simoens, C ^a   Van Damme, P ^b   Scharpantgen, A ^c   Meijer, C J L M ^d   Beutels, P ^b,e  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c Ministry of Health   (Luxembourg)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Belgium; Cervical cancer prevention; European Union; HPV vaccination; Luxembourg; The Netherlands

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; BELGIUM; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER SCREENING; CHILD; CLINICAL TRIAL; DRUG COST; FEMALE; HEALTH CARE DELIVERY; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; LUXEMBOURG; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MULTICENTER STUDY; NETHERLANDS; PRIORITY JOURNAL; REIMBURSEMENT; SCHOOL CHILD; UTERINE CERVIX CANCER;

ADOLESCENT; BELGIUM; CHILD; FEMALE; HEALTH POLICY; HUMANS; LUXEMBOURG; MASS VACCINATION; NETHERLANDS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; REIMBURSEMENT MECHANISMS; UTERINE CERVICAL DISEASES; UTERINE CERVICAL NEOPLASMS;

EID: 78649711797     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314010     Document Type: Article

References (36)

1. Arbyn M, Dillner J: Review of current knowledge on HPV vaccination: An appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. J Clin Virol 2007;38:189-197.
2. Giannini SL, Hanon E, Moris P, et al: Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006;24:5937-5949.
3. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ: Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-285.
4. Parkin DM, Bray F: Chapter 2: The burden of HPV-related cancers. Vaccine 2006;24(suppl 3): S11-S25.
5. Lacey CJ, Lowndes CM, Shah KV: Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006;24:35-41.
6. Ault KA: Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369:1861-1868.
7. Harper DM, Franco EL, Wheeler CM, et al: Sustained efficacy up to 4-5 years of bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-1255.
8. Paavonen J, Jenkins D, Bosch FX, et al: Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-2170.
9. FUTURE II Study Group: Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-1927.
10. Hildesheim A, Herrero R, Wacholder S, et al: Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007;298:743-753.
11. King LA, Levy-Bruhl D, O'Flanagan D, Bacci S, Lopalco PL, Kudjawu Y, Salmaso S: Introduction of human papillomavirus (HPV) vaccination into national immunisation schedules in Europe: results of the VENICE 2007. survey. Euro Surveill 2008;13:1-6.
12. Koulova A, Tsui J, Irwin K, Van Damme P, Biellik R, Aguado MT: Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006 to January 2008. Vaccine 2008.
13. Arbyn M, Benoy IH, Simoens C, Beutels P, Bogers J, Depuydt C: Pre-vaccination distribution of HPV types in women attending at cervical cancer screening in Belgium. Cancer Epidemiol Biomarkers Prev 2009;20:321-330.
14. Sargent A, Bailey A, Almonte M, et al: Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. Br J Cancer 2008.
15. Arbyn M: Effects of quadrivalent human papillomavirus vaccination. Lancet 2007;370:1031-1032.
16. Newall AT, Beutels P, Wood JG, Edmunds WJ, MacIntyre CR: Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis 2007;7:289-296.
17. Kim JJ, Goldie SJ: Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008;359:821-832.
18. Arbyn M, Raifu AO, Autier P, Ferlay J: Burden of cervical cancer in Europe: estimates for 2004. Ann Oncol 2007;18:1708-1715. (Pubitemid 47506260)
19. Arbyn M, Raifu AO, Bray F, Weiderpass E, Anttila A: Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer 2009;45:2640-2648.
20. Hoge Gezondheidsraad, Conseil Supérieur de la Santé. Vaccinatie tegen infecties veroorzaakt door het humaan papillomavirus/ Vaccination contre les infections causées par le papillomavirus humain. Publicatie van de Hoge GezondheidsRaad/Publication du Conseil supérieur de la Santé 2007;8367, update of 8204:1-51. Accessible at:: http://www.health.fgov. be/HGR-CSS
21. Onkelinx L: Nationaal Kankerplan. Ministry of Public Health and Soical Affairs, 2008. Accessible at: http://www.laurette-onkelinx. be/articles-docs/32- initiatieven-N.pdf
22. Direction de la Santé (Grand-Duché du Luxembourg): Nouveau Programme de vaccination contre le Human Papilloma Virus (HPV), 2008. Accessible at: http://www.dmp. public.lu/actualites/2008/02/vacc-hpv/index.html
23. Gezondheidsraad: Vaccinatie tegen baarmoederhalskanker. Den Haag, 2008. Accessible at: http://www.gr.nl/pdf.php?ID=1700&p=1
24. Thiry N, Lambert ML, Cleemput I, Huybrechts M, Neyt M, Hulstaert F, De Laet C: Vaccination HPV pour la prévention du cancer du col de l'utérus en Belgique: Health Technology Assessment. Brussels, Centre fédéral d'Expertise des Soins de Santé, 2009. Accessible at: http://www.kce.fgov. be/index-fr.aspx?SGREF=3461&CREF=9990
25. FitzSimons D, Vorsters A, Hoppenbrouwers K, Van Damme P: Prevention and control of viral hepatitis through adolescent health programmes in Europe. Vaccine 2007;25:8651-8659.
26. Boeke AJ: Advisory report from the Health Council of the Netherlands to include human papillomavirus vaccination in the national immunisation programme for the prevention of cervical cancer. Ned Tijdschr Geneeskd 2008;152:981-983.
27. van der Aa MA, de Kok IM, Siesling S, van Ballegooijen M, Coebergh JW: Does lowering the screening age for cervical cancer in The Netherlands make sense? Int J Cancer 2008;123:1403-1406.
28. Arbyn M, Simoens C, Van Oyen H, Foidart J-M, Goffin F, Simon P, Fabri V: Analysis of 13 million individual patient records pertaining to Pap smears, colposcopies, biopsies and surgery on the uterine cervix (Belgium, 1996-2000). Prev Med 2009;48:438-443.
29. Rebolj M, van Ballegooijen M, Berkers LM, Habbema J D F: Monitoring a national cancer prevention programme: successful changes in cervical cancer screening in the Netherlands. Int J Cancer 2006;120:806-812.
30. Arbyn M, Rebolj M, de Kok IM, Becker N, O'Reilly M, Andrae B: Challenges for organising cervical screening programmes in the 15 old member states of the European Union. Eur J Cancer 2009;45:2671-2678.
31. Scheiden R, Knolle U, Wagener C, Wehenkel AM, Capesius C: Cervical cancer screening in Luxembourg. Eur J Cancer 2000;36:2240-2243.
32. Bentham G, Hinton J, Haynes R, Lovett A, Bestwick C: Factors affecting non-response to cervical cytology screening in Norfolk, England. Soc Sci Med 1995;40:131-135.
33. Arbyn M, Quataert P, Van Hal G, Van Oyen H: Cervical cancer screening in the Flemish Region (Belgium): measurement of the attendance rate by telephone interview. Eur J Cancer Prev 1997;6:389-398.
34. Lindau ST, Tomori C, Lyons T, Langseth L, Bennett CL, Garcia P: The association of health literacy with cervical cancer prevention knowledge and health behaviors in a multiethnic cohort of women. Am J Obstet Gynecol 2002;186:938-943.
35. European Commission: European Guidelines for Quality Assurance in Cervical Cancer Screening, ed 2. Luxembourg, Office for Official Publications of the European Communities, 2008.
36. Vandermeulen C, Roelants M, Theeten H, Depoorter AM, Van Damme P, Hoppenbrouwers K: Vaccination coverage in 14-yearold adolescents: documentation, timeliness, and sociodemographic determinants. Pediatrics 2008;121: e428-e434.